3-10-2019 jacob plieth vantage

US approves immunotherapy for breast cancer for first time

Roche’s cancer immunotherapy Tecentriq (atezolizumab), a PD-L1 inhibitor, scored its fifth Food and Drug Administration approval on [March 8], for advanced triple-negative ...